Childhood acute lymphoblastic leukemia in the Middle East and neighboring countries: A prospective multi-institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance (MECCA)

dc.contributor.authorAl-Mulla, Naima Ali
dc.contributor.authorChandra, Prem
dc.contributor.authorKhattab, Mohammed
dc.contributor.authorMadanat, Faris F.
dc.contributor.authorVossough, Parvaneh
dc.contributor.authorTorfa, Eyad
dc.contributor.authorAl-Lamki, Zakia M.N.
dc.contributor.authorZain, Gamal Hussien
dc.contributor.authorMuwakkit, Samar A.
dc.contributor.authorMahmoud, Salah
dc.contributor.authorAl-Jassmi, Abdulrahman
dc.contributor.authorTuncer, Murat Asli
dc.contributor.authorAl-Mukharraq, Hussain J.
dc.contributor.authorBarsaoui, Siheme
dc.contributor.authorArceci, Robert J.
dc.contributor.authorHoward, Scott C.
dc.contributor.authorKulozik, Andreas E.
dc.contributor.authorRavindranath, Yaddanapudi
dc.contributor.authorReaman, Gregory H.
dc.contributor.authorFaranoush, Mohammad
dc.contributor.authorAlnasser, Abdullah A.
dc.contributor.departmentPediatrics and Adolescent Medicine
dc.contributor.departmentDivision of Pediatric Hematology-Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:10:30Z
dc.date.available2025-01-24T12:10:30Z
dc.date.issued2014
dc.description.abstractBackground: Little is known about childhood ALL in the Middle East. This study was undertaken by MECCA as initial efforts in collaborative data collection to provide clinical and demographic information on children with ALL in the Middle East. Procedure: Clinical and laboratory data for patients with ALL between January 2008 and April 2012 were prospectively collected from institutions in 14 Middle East countries and entered into a custom-built-database during induction phase. All laboratory studies including cytogenetics were done at local institutions. Results: The 1,171 voluntarily enrolled patients had a mean age of 6.1±3.9 years and 59.2% were boys. T-ALL represented 14.8% and 84.2% had B-precursor ALL. At diagnosis, 5.6% had CNS disease. The distribution of common genetic abnormalities reflected a similar percentage of hyperdiploidy (25.6%), but a lower percentage of ETV6-RUNX1 translocation (14.7%) compared to large series reported from Western populations. By clinical criteria, 47.1% were low/standard risk, 16.9% were intermediate risk, and 36% were high risk. Most patients received all their care at the same unit (96.9%). Patients had excellent induction response to chemotherapy with an overall complete remission rate of 96%. Induction toxicities were acceptable. Conclusions: This first collaborative study has established a process for prospective data collection and future multinational collaborative research in the Middle East. Despite the limitations of an incomplete population-based study, it provides the first comprehensive baseline data on clinical characteristics, laboratory evaluation, induction outcome, and toxicity. Further work is planned to uncover possible biologic differences of ALL in the region and to improve diagnosis and management. Pediatr Blood Cancer 2014; 61:1403-1410. © 2014 Wiley Periodicals, Inc.
dc.identifier.doihttps://doi.org/10.1002/pbc.25031
dc.identifier.eid2-s2.0-84901988987
dc.identifier.pmid24648275
dc.identifier.urihttp://hdl.handle.net/10938/32307
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofPediatric Blood and Cancer
dc.sourceScopus
dc.subjectInduction
dc.subjectLeukemia
dc.subjectMecca
dc.subjectPediatric
dc.subjectAdolescent
dc.subjectChild
dc.subjectChild, preschool
dc.subjectCore binding factor alpha 2 subunit
dc.subjectDisease-free survival
dc.subjectFemale
dc.subjectHumans
dc.subjectInfant
dc.subjectMale
dc.subjectMiddle east
dc.subjectOncogene proteins, fusion
dc.subjectPrecursor cell lymphoblastic leukemia-lymphoma
dc.subjectSurvival rate
dc.subjectTranslocation, genetic
dc.subjectAntineoplastic agent
dc.subjectBcr abl protein
dc.subjectHemoglobin
dc.subjectPhosphorus
dc.subjectPotassium
dc.subjectTranscription factor 7 like 1
dc.subjectTranscription factor etv6
dc.subjectTranscription factor pbx1
dc.subjectTranscription factor runx1
dc.subjectUric acid
dc.subjectAcute lymphoblastic leukemia
dc.subjectAdult
dc.subjectAnaphylaxis
dc.subjectArticle
dc.subjectAvascular necrosis
dc.subjectBleeding
dc.subjectBone marrow
dc.subjectBone necrosis
dc.subjectBone pain
dc.subjectBronchospasm
dc.subjectCancer chemotherapy
dc.subjectCancer mortality
dc.subjectChildhood leukemia
dc.subjectComorbidity
dc.subjectConstipation
dc.subjectCytogenetics
dc.subjectDiarrhea
dc.subjectDiploidy
dc.subjectDown syndrome
dc.subjectFever
dc.subjectFlow cytometry
dc.subjectFluorescence in situ hybridization
dc.subjectGastritis
dc.subjectGene rearrangement
dc.subjectGene translocation
dc.subjectGenetic risk
dc.subjectGram negative sepsis
dc.subjectGram positive sepsis
dc.subjectHeart arrhythmia
dc.subjectHeart failure
dc.subjectHematologic disease
dc.subjectHepatomegaly
dc.subjectHuman
dc.subjectHuman cell
dc.subjectHyperdiploidy
dc.subjectImmune deficiency
dc.subjectImmunophenotyping
dc.subjectInduction chemotherapy
dc.subjectKaryotyping
dc.subjectLeukemia remission
dc.subjectLeukocyte count
dc.subjectLymphadenopathy
dc.subjectMajor clinical study
dc.subjectMotor neuropathy
dc.subjectMycosis
dc.subjectMyelodysplastic syndrome
dc.subjectOral mucositis
dc.subjectOsteoporosis
dc.subjectPallor
dc.subjectPancreatitis
dc.subjectParalysis
dc.subjectPetechia
dc.subjectPolymerase chain reaction
dc.subjectPre b lymphocyte
dc.subjectPriority journal
dc.subjectScrotal swelling
dc.subjectSeizure
dc.subjectSensory neuropathy
dc.subjectSepsis
dc.subjectShock
dc.subjectSkin bruising
dc.subjectSplenomegaly
dc.subjectSteroid therapy
dc.subjectThrombocyte count
dc.subjectTreatment response
dc.subjectTumor lysis syndrome
dc.subjectTyphlitis
dc.subjectUrticaria
dc.titleChildhood acute lymphoblastic leukemia in the Middle East and neighboring countries: A prospective multi-institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance (MECCA)
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2014-10556.pdf
Size:
1.04 MB
Format:
Adobe Portable Document Format